BioSpace News Archive

Cyxone AB (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that it has initiated a process to optimize the development plan for Rabeximod.

A broad array of consumer, medical, parents, and environmental groups are lauding a new safety communication from the U.S. Food and Drug Administration that recommends against use of dental amalgam in children and many women.

Today, the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration took actions to help provide safe, effective, and more affordable drugs

Bio Health Worldwide Online , taking place from 19 th to 30 th of October 2020 , is designed to overcome the travel restrictions and facilitate networking opportunities for global health companies from all around the world. Regarded as th

Neurophth Therapeutics, Inc., (hereinafter referred to as “Neurophth”) today announced that its leading candidate, NR082 (rAAV2-ND4, NFS-01 project), was granted an orphan drug designation (ODD) by the U.S. FDA for the treatment of Leber’s Hereditary Optic Neuropathy associated with ND4 mutation. Leber’s Hereditary O